# Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

> **NCT04744649** · PHASE2 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 110 (estimated)

## Conditions studied

- Gastric Cancer
- Stomach Neoplasm

## Interventions

- **DRUG:** XELOX or SOX
- **DRUG:** JS001+XELOX or SOX

## Key facts

- **NCT ID:** NCT04744649
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-12
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2022-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04744649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04744649, "Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04744649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*